Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troculeucel (SNK01) Safety and Efficacy in Refractory Cancer
NCT03941262Phase 1Completed
- Sponsor
- NKGen Biotech
- Start
- Jul 2019
- Primary completion
- Feb 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of troculeucel in solid tumor (5 arms), sponsored by NKGen Biotech. Primary endpoint: Safety Profile at 6 months. Started Jul 2019; status: completed.
02
Drugs
troculeucel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03941262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941262.